Predict your next investment

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

About Kirin Pharma Company

As of April 1, 2008, Kirin Pharma Company, Limited was acquired by Kyowa Hakko Kogyo Co., Ltd. Kirin Pharma Company, Limited manufactures bio-pharmaceutical products. It focuses on renal, cancer, and immune disorder and infectious diseases. It is now headquartered in Japan.

Kirin Pharma Company Headquarter Location

9420 Athena Circle

La Jolla, California, 92037,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Kirin Pharma Company Investments

3 Investments

Kirin Pharma Company has made 3 investments. Their latest investment was in CoImmune as part of their Debt - II on September 9, 2010.

CBI Logo

Kirin Pharma Company Investments Activity

investments chart

Kirin Pharma Company Portfolio Exits

1 Portfolio Exit

Kirin Pharma Company has 1 portfolio exit. Their latest portfolio exit was CoImmune on February 07, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/7/2014

IPO

$99M

3

Date

2/7/2014

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

3

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.